Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 9, 1997, Pages 1756-1764

  Lefebvre, Anne Marie ^a   Peinado Onsurbe, Julia ^b   Leitersdorf, Iris ^a   Briggs, Michael R ^c   Paterniti, James R ^c   Fruchart, Jean Charles ^a   Fievet, Catherine ^a   Auwerx, Johan ^a   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Atherosclerosis; Gene regulation; Hypolipidemic drugs; PPAR; Triglycerides

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; APOLIPOPROTEIN C3; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; LIPOPROTEIN LIPASE; MESSENGER RNA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HYPERLIPIDEMIA; INTRAGASTRIC DRUG ADMINISTRATION; LIPOPROTEIN METABOLISM; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RNA ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030848473     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.9.1756     Document Type: Article

References (18)

1. Hofmann CA, Colca JR. New oral thiazolidinedionc antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992;15:1075-1078.
2. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Drug Res. 1990;40:156-162.
3. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-(4-(l-methylcycIohexylmethoxy)benzyl)thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804-810.
4. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes. 1983;32:830-838.
5. Sohda T, Mizuno K, Momose Y, Ikeda H, Fujita T, Meguro K. Studies on antidiabetic agents. 11. Novel thiazolidinedione deriv-atives as potent hypoglycemic and hjpolipidemic agents. J Med Chem. 1992;35:2617-2626.
6. Stevenson RW, Hutson NJ, Krupp MM, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, et al. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes. 1990;39: 1218-1227.
7. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes. 1995;44: 1087-1092.
8. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
9. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
10. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes. 1994;43:204-211.
11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953-12956.
12. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
13. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator activated receptor gene family from mouse liver. J Biol Chem. 1993;268:26817-26820.
14. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
15. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
16. Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc Royal Soc Land [Biol]. 1992;247:83-87.
17. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPARα, β and γ in the adult rat. Endocrinology. 1995;137:354-366.
18. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory elements in the peroxisome proliferator-responsive element enhancer region of rat acyl-CoA Oxidase gene. Biochem Biophys Res Commun. 1991;175:866-871.